Recently, Janssen announced that their drug candidate Seltorexant has successfully completed a Phase III study showing significant improvements in patients with major depressive disorder and insomnia. Seltorexant, an orexin-2 receptor antagonist, reduced depression symptoms and improved sleep on the 43rd day of treatment, was safe and well tolerated.
 

The bridge core of Seltorexant is an octahydropyrrolo[3,4-C]pyrrole fragment.

To expand your further research we have created a set of analogs to this interesting bicyclic moiety.

For all the details, contact us at info@chem-space.com.